Novartis Strikes Liver Disease Deal and Buys Encore Vision

Dec 20, 2016

Novartis is closing the year out strong, as the drugmaker signs a licensing deal to co-develop a fatty liver disease drug with Conatus Pharmaceuticals, as well as announces a buyout of Texas opthalmology startup, Encore Vision.

The $50 million up front agreement with California-based Conatus will enable the companies to jointly develop Conatus' drug, emricasan, an experimental first-in-class oral treatment for non-alcoholic steatohepatitis (NASH) with advanced fibrosis and cirrhosis.

The Encore Vision purchase, of which the financials were not disclosed, will enable Novartis to focus on developing a novel treatment for presbyopia -- far-sightedness -- giving Novartis access to Encore's lead investigational product EV06, an innovative topical treatment for presbyopia.


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments